Loading...
•
Mar 31
AptarGroup Q1 2025 Earnings Report
AptarGroup reported a modest decline in revenue and earnings compared to the prior year quarter.
Key Takeaways
AptarGroup's Q1 2025 results showed a slight revenue decline and lower net income, driven by weaker performance in Beauty and Closures segments, partially offset by strong demand in Pharma, especially for emergency medicine and diabetes care solutions.
Revenue declined 3% YoY to $887.3M due to lower sales in Beauty and Closures.
Pharma segment saw continued demand for emergency and chronic condition drug delivery systems.
Adjusted EBITDA margin improved to 20.7%, driven by margin expansion in Pharma and Closures.
Returned $110M to shareholders via dividends and repurchases, buying back 548K shares.
AptarGroup
AptarGroup
AptarGroup Revenue by Segment
Revenue by Segment
Aptar Pharma Revenue
CapyFin.comAptar Beauty Revenue
CapyFin.comAptar Closures Revenue
CapyFin.com Forward Guidance
Aptar expects EPS between $1.56 and $1.64 for Q2 2025, supported by broad segment growth and one-time tax benefits.
Positive Outlook
- Anticipates contributions from all three business segments.
- Positioned well across resilient end markets such as chronic disease medications.
- Increased agility due to in-region supply chain structure.
- Second quarter earnings expected to benefit from a favorable tax rate (19–21%).
- Continued demand in Pharma segment, especially for CNS and emergency medicine products.
Challenges Ahead
- Macroeconomic uncertainty could affect consumer and industrial demand.
- Ongoing challenges in beauty dispensing technologies may persist.
- Reduced tooling sales and discontinued operations may continue to impact Closures.
- Currency fluctuations could affect results despite hedging.
- Elevated tax rate in Q1 from French surtax highlights future tax policy risk.